W Robert Lee

List of Publications by Year in Descending Order

76 papers	2,887 citations	28 h-index	53 g-index
83 ext. papers	3,415 ext. citations	3.4 avg, IF	4.73 L-index

#	Paper	IF	Citations
76	Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer.. *Advances in Radiation Oncology*, **2022**, 7, 100805	3.3	0
75	Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.. *Journal of Clinical Oncology*, **2022**, 40, 243-243	2.2	
74	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. *PLoS ONE*, **2021**, 16, e0249123	3.7	0
73	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. *Journal of Clinical Oncology*, **2021**, 39, 136-144	2.2	17
72	Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415.. *Journal of Clinical Oncology*, **2021**, 39, 60-60	2.2	
71	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.. *JAMA Network Open*, **2021**, 4, e2139769	10.4	2
70	Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.. *Journal of Clinical Oncology*, **2020**, 38, 327-327	2.2	
69	A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415.. *Journal of Clinical Oncology*, **2020**, 38, 55-55	2.2	
68	Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.. *Journal of Clinical Oncology*, **2020**, 38, 5584-5584	2.2	1
67	Multi-Institutional Analysis of Synchronous Prostate and Rectosigmoid Cancers. *Frontiers in Oncology*, **2020**, 10, 345	5.3	1
66	Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. *Radiotherapy and Oncology*, **2019**, 135, 19-24	5.3	15
65	A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 834-842	4	9
64	Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.. *Journal of Clinical Oncology*, **2019**, 37, 29-29	2.2	2
63	Multi-institutional analysis of synchronous prostate and rectosigmoid cancers.. *Journal of Clinical Oncology*, **2019**, 37, 33-33	2.2	
62	Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2019**, 5, 664-670	13.4	17
61	Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 396-405	4	11
60	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. *JAMA Oncology*, **2018**, 4, e175230	13.4	49

59	Moderate hypofractionation for prostate cancer. *Translational Andrology and Urology*, **2018**, 7, 321-329	2.3	3
58	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. *European Urology*, **2018**, 74, 99-106	10.2	18
57	Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1504-1515	21.7	82
56	Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. *Radiation Oncology*, **2017**, 12, 14	4.2	24
55	Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 473-480	4	14
54	A nomogram for testosterone recovery following combined androgen deprivation therapy and radiation therapy for prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 67-67	2.2	
53	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. *Journal of Clinical Oncology*, **2016**, 34, 3648-3654	2.2	200
52	Invited commentary on GETUG-AFU 16. *Translational Andrology and Urology*, **2016**, 5, 958-960	2.3	3
51	Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. *Journal of Clinical Oncology*, **2016**, 34, 2325-32	2.2	315
50	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 1046-1053	4	34
49	Quantitative comparison of automatic and manual IMRT optimization for prostate cancer: the benefits of DVH prediction. *Journal of Applied Clinical Medical Physics*, **2015**, 16, 5204	2.3	7
48	Atlas-guided prostate intensity modulated radiation therapy (IMRT) planning. *Physics in Medicine and Biology*, **2015**, 60, 7277-91	3.8	15
47	Hypofractionation for clinically localized prostate cancer. *Seminars in Radiation Oncology*, **2013**, 23, 191-7	5.5	20
46	Single institution dosimetry and IGRT analysis of prostate SBRT. *Radiation Oncology*, **2013**, 8, 215	4.2	17
45	Strategies for automatic online treatment plan reoptimization using clinical treatment planning system: a planning parameters study. *Medical Physics*, **2013**, 40, 111711	4.4	10
44	Intensity-Modulated Radiotherapy **2013**, 749-759		
43	Image guidance for post-prostatectomy radiotherapy: Are we missing the mark?. *Journal of Clinical Oncology*, **2013**, 31, 56-56	2.2	
42	Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 200-3	4	17

41	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. *Brachytherapy*, **2012**, 11, 6-19	2.4	342
40	Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans. *Medical Physics*, **2012**, 39, 6868-78	4.4	188
39	Radiotherapy following radical prostatectomy. *Expert Review of Anticancer Therapy*, **2012**, 12, 973-9	3.5	2
38	Salvage radiation in men after prostate-specific antigen failure and the risk of death. *Cancer*, **2011**, 117, 3925-32	6.4	76
37	American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 335-41	4	59
36	The development of oncology treatment guidelines: an analysis of the National Guidelines Clearinghouse. *Practical Radiation Oncology*, **2011**, 1, 33-7	2.8	
35	Adaptive prostate IGRT combining online re-optimization and re-positioning: a feasibility study. *Physics in Medicine and Biology*, **2011**, 56, 1243-58	3.8	38
34	On-line adaptive radiation therapy: feasibility and clinical study. *Journal of Oncology*, **2010**, 2010, 407236	4.5	16
33	Seduced by dose?. *Journal of Clinical Oncology*, **2010**, 28, 1087-9	2.2	1
32	Comparison of online IGRT techniques for prostate IMRT treatment: adaptive vs repositioning correction. *Medical Physics*, **2009**, 36, 1651-62	4.4	51
31	Extreme hypofractionation for prostate cancer. *Expert Review of Anticancer Therapy*, **2009**, 9, 61-5	3.5	16
30	Hypofractionation for prostate cancer: a critical review. *Seminars in Radiation Oncology*, **2008**, 18, 41-7	5.5	80
29	On-line re-optimization of prostate IMRT plans for adaptive radiation therapy. *Physics in Medicine and Biology*, **2008**, 53, 673-91	3.8	97
28	Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. *Cancer*, **2007**, 109, 1506-12	6.4	54
27	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. *Brachytherapy*, **2007**, 6, 2-8	2.4	43
26	Prostate brachytherapy: a descriptive analysis from CaPSURE. *Brachytherapy*, **2007**, 6, 123-8	2.4	4
25	A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 199-204	2.7	4
24	Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. *Urology*, **2006**, 67, 349-53	1.6	18

23	Update on brachytherapy in localized prostate cancer: the importance of dosimetry. *Current Opinion in Urology*, **2006**, 16, 157-61	2.8	6
22	A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. *Brachytherapy*, **2006**, 5, 239-43	2.4	17
21	A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 804-9	4	34
20	What variables predict for metastasis in men with biochemical relapse following radiotherapy for prostate cancer?. *Nature Clinical Practice Oncology*, **2005**, 2, 340-1		3
19	Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 956-64	4	50
18	Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?. *Brachytherapy*, **2005**, 4, 252-8	2.4	47
17	Dosimetry and cancer control after low-dose-rate prostate brachytherapy. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 52-9	4	11
16	Medical malpractice and prostate brachytherapy. *Brachytherapy*, **2004**, 3, 237-9	2.4	1
15	Changes in graduate medical education: a view from radiation oncology. *Journal of the American College of Radiology*, **2004**, 1, 576-82	3.5	2
14	Permanent prostate brachytherapy: the significance of postimplant dosimetry. *Reviews in Urology*, **2004**, 6 Suppl 4, S49-56	1	2
13	The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. *Cancer*, **2003**, 98, 1987-94	6.4	50
12	Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. *Brachytherapy*, **2002**, 1, 90-4	2.4	41
11	Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 457-61	4	102
10	The role of androgen deprivation therapy combined with prostate brachytherapy. *Urology*, **2002**, 60, 39-44; discussion 44	1.6	27
9	Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. *Cancer*, **1997**, 79, 75-80	6.4	52
8	Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survival. *Journal of Urology*, **1996**, 156, 450-453	2.5	101
7	Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. *Cancer*, **1996**, 77, 1334-41	6.4	28
6	Pretreatment serum prostate-specific antigen (PSA) level and PSA doubling times (PSADT) in black and white men with prostate cancer referred for radiation therapy. *Radiation Oncology Investigations*, **1996**, 4, 135-139		

5	Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam Radiation. *Journal of Urology*, **1995**, 154, 456-459	2.5	95
4	Radiation therapy following radical prostatectomy. *Cancer*, **1995**, 75, 1909-1913	6.4	5
3	External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990. *Cancer*, **1995**, 75, 1972-1977	6.4	32
2	Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. *Journal of Urology*, **1994**, 152, 1775-80	2.5	53
1	Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. *Cancer*, **1993**, 72, 3156-73	6.4	85